American Society of Clinical Oncology (ASCO)
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network. ORLANDO, F...
Guiyang hosts 20th Guizhou Tourism Industry Development Conference
GUIYANG, China, March 31, 2026 /PRNewswire/ -- A news report from China Daily:
Co-PSMA data published in the European Urology journal
SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...
3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Rapid Advancement Across Core R&D Pipeline * The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent...
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: * Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with23% i...
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...
Wolfbox® Debuts at 60th Easter Jeep Safari With Off-Road Visibility Tech Showcase
Also a sponsor for three iconic Moab trail runs at America's premier off-road
event, Wolfbox will host an interactive booth to spotlight the brand's off-road
visibility technology and trail-ready gear.
MOAB, Utah, March 25, 2026 /PRNewswire/ -- Wolfbox
DualityBio (9606.HK) Announces 2025 Annual Results
HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. * R&D Expenses was approximately RMB1319.68 million. * Loss for the period was RMB381.97 million, adjusted annual loss[1] was approxim...
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion....
Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also know...
Connecting the World, Empowering the Future
CAC2026 Opened in Shanghai, Building a Global Ecosystem for the Entire Crop Inputs Industry Chain SHANGHAI, March 17, 2026 /PRNewswire/ -- The 26th China International Agrochemical & Crop Protection Exhibition (CAC2026) grandly opened onMarch 17 at National Exhibition and Convention Center (Shan...
Registrational Phase III AMPLIFY trial: Target number of participants achieved
SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...
CARsgen Therapeutics Announces 2025 Annual Results
SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights * Cash and cash equivalents were around RMB1,123 million as of Decemb...
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
* Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer * Novel combination therapy will be studied as part of the Phase II adaptive pl...
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself,me...
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 291 media titles]
2026-07-30 09:12
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 290 media titles]
2026-07-27 19:02
